ArticleFrontiers in pharmacology2025
CFTR ion transport deficiency primes the epithelium for partial epithelial-mesenchymal transition in cystic fibrosis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell-State Plasticity in the CFTR Modulator Era.Cell proliferation · 2026Review
- Cx43 levels guide apicobasal polarity in regenerating airway epithelial cells.Communications biology · 2026Article
- Host-Pathogen Interactions in Cystic Fibrosis Lung Disease: Adaptation, Persistence, and Clinical Implications ofPathogens (Basel, Switzerland) · 2026Review
- Huangjin Shuangshen decoction alleviates chronic atrophic gastritis by suppressing TNF/NF-κB signaling and promoting CFTR-associated gastric mucosal barrier repair.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cystic fibrosis (CF) is a monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a Cl Methods: Here, we investigated whether PM localisation of CFTR alone is sufficient to preserve epithelial integrity or if its ion transport function is also required using polarized CF bronchial epithelial (CFBE) cells expressing wt-, p.Phe508del-, or p.Gly551Asp-CFTR. While p.Phe508del-CFTR is retained in the endoplasmic reticulum (ER) and fails to traffic to the PM, p.Gly551Asp-CFTR reaches the PM but lacks ion transport function. To this end we assessed transepithelial electrical resistance (TEER), cell proliferation, wound healing, and expression of epithelial and mesenchymal markers by Western blot and immunofluorescence. Results: The degree of mesenchymal phenotype was higher in cells expressing p.Phe508del-CFTR vs. those expressing PM localized but non-functional p.Gly551Asp-CFTR. This was evidenced by lower TEER, higher expression of mesenchymal markers (N-cadherin, vimentin), and lower E-/N-cadherin ratio. Furthermore, both CF cells displayed delayed wound healing compared to wt-CFTR cells, while only p.Phe508del-CFTR cells, but not p.Gly551Asp-CFTR cells, showed increased cell proliferation. Moreover, treatment with CFTR modulators (CFTRm) partially restored tight junction integrity by increasing claudin-1 levels and E-/N-cadherin ratio in both mutant cells. TGF-β1 treatment induced EMT in all three cell lines by decreasing epithelial markers (E-cadherin, cytokeratin 18, claudin-1) while increasing N-cadherin levels. However, mesenchymal marker vimentin increased only in CF cells, and more prominently in p.Phe508del-CFTR than in p.Gly551Asp-CFTR cells. Additionally, CFTR inhibition in wt-CFTR cells, partially mimicked p.Gly551Asp-CFTR behaviour, i.e., reduced claudin-1 levels. Discussion: Altogether, these findings demonstrate that the loss of CFTR ion transport, despite the physical presence of (nonfunctional) CFTR at the PM, is enough to trigger partial EMT. However, the severity of the EMT phenotype worsens when CFTR is absent from the PM while also increasing susceptibility to TGF-β1-triggered EMT. Moreover, CFTRm only partially reverse this CF EMT state, indicating that full epithelial integrity will likely require targeting additional factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.